Cancer treatment firm Sirtex Medical said that a preliminary analysis of its SIRFLOX clinical study found that its SIR-Spheres yttrium-90 (Y-90) resin microspheres did not yield a statistically significant improvement in overall progression-free survival for treating nonresectable metastatic colorectal cancer.
However, the study did show a statistically significant improvement in progression-free survival in the liver, according to the vendor. The study evaluated the addition of the company's SIR-Spheres Y-90 microspheres to a current first-line systemic chemotherapy regimen for treating nonresectable metastatic colorectal cancer.
Despite the primary end point not being achieved, the improvement in progression-free survival in the liver is important, as the organ is commonly the only or dominant disease site in patients with nonresectable metastatic colorectal cancer, Sirtex said. It's also the major site of disease affecting survival, according to the company.
Sirtex noted that the SIRFLOX study results and preliminary analysis still require verification through the academic peer review process. Final results will be submitted for presentation at the American Society of Clinical Oncology (ASCO) annual meeting in May.
